John Theurer Cancer Center | Strategic Alliance Partners

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.

James K. McCloskey, MD, discusses the efficacy of oral decitabine plus cedazuridine, the combination’s potential role in lower-risk myelodysplastic syndromes, and what this could mean for the patient population.

Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.

Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.

Noa Biran, MD, discusses her predictions for where the field of multiple myeloma is headed as well as some of these agents that have generated excitement for patient populations that are currently an unmet need.

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Innovative robotic technology helps to improve surgical outcomes and safety for patients while advancing the field of ENT surgery.

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.

Andrew Ip, MD, MS, discusses remaining questions with the COVID-19 vaccine in patients with cancer.

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

As James K. McCloskey II, MD, begins the next chapter of his career as chief of the Division of Leukemia at John Theurer Cancer Center at Hackensack University Medical Center.

Department of Urology uses bioregenerative medicine to improve erectile function and continence after robotic radical prostatectomy.

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.